We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+1.69%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$22.4B
AUM Growth
+$745M
Cap. Flow
+$687M
Cap. Flow %
3.07%
Top 10 Hldgs %
31.51%
Holding
1,352
New
72
Increased
666
Reduced
342
Closed
71

Top Buys

Rank Stock Value
1
AMT icon
American Tower
AMT
+$191M
2
MSFT icon
Microsoft
MSFT
+$116M
3
NVDA icon
NVIDIA
NVDA
+$115M
4
AAPL icon
Apple
AAPL
+$108M
5
WY icon
Weyerhaeuser
WY
+$83.8M

Sector Composition

Rank Sector Weight
1 Real Estate 37.54%
2 Technology 23.33%
3 Communication Services 8.01%
4 Consumer Discretionary 6.37%
5 Financials 5.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BEAM icon
1126
Beam Therapeutics
BEAM
$2.65B
$7K ﹤0.01%
283
DVAX
1127
DELISTED
Dynavax Technologies
DVAX
$7K ﹤0.01%
529
HRMY icon
1128
Harmony Biosciences
HRMY
$2.07B
$7K ﹤0.01%
189
IBRX icon
1129
ImmunityBio
IBRX
$7.16B
$7K ﹤0.01%
2,620
IRON icon
1130
Disc Medicine
IRON
$2.79B
$7K ﹤0.01%
113
LGND icon
1131
Ligand Pharmaceuticals
LGND
$5.88B
$7K ﹤0.01%
63
MNKD icon
1132
MannKind Corp
MNKD
$1.2B
$7K ﹤0.01%
1,058
ARQT icon
1133
Arcutis Biotherapeutics
ARQT
$3.5B
$6K ﹤0.01%
439
CGON icon
1134
CG Oncology
CGON
$6.14B
$6K ﹤0.01%
+223
New +$7.63K
FTRE icon
1135
Fortrea Holdings
FTRE
$1.96B
$6K ﹤0.01%
328
GPCR icon
1136
Structure Therapeutics
GPCR
$3.39B
$6K ﹤0.01%
226
INDV icon
1137
Indivior Pharmaceuticals
INDV
$4.84B
$6K ﹤0.01%
+450
New +$4.63K
NMRA icon
1138
Neumora Therapeutics
NMRA
$302M
$6K ﹤0.01%
+533
New +$6.39K
TARS icon
1139
Tarsus Pharmaceuticals
TARS
$2.55B
$6K ﹤0.01%
107
WVE icon
1140
Wave Life Sciences
WVE
$1.12B
$6K ﹤0.01%
503
+154
+44% +$2.06K
XLC icon
1141
State Street Communication Services Select Sector SPDR ETF
XLC
$22.5B
$6K ﹤0.01%
61
+47
+336% +$4.48K
ARVN icon
1142
Arvinas
ARVN
$525M
$5K ﹤0.01%
252
AUPH icon
1143
Aurinia Pharmaceuticals
AUPH
$1.92B
$5K ﹤0.01%
528
BCRX icon
1144
BioCryst Pharmaceuticals
BCRX
$2.43B
$5K ﹤0.01%
692
CNTA
1145
DELISTED
Centessa Pharmaceuticals
CNTA
$5K ﹤0.01%
294
+83
+39% +$1.38K
NRIX icon
1146
Nurix Therapeutics
NRIX
$2.44B
$5K ﹤0.01%
245
NVAX icon
1147
Novavax
NVAX
$1.2B
$5K ﹤0.01%
652
OCUL icon
1148
Ocular Therapeutix
OCUL
$1.83B
$5K ﹤0.01%
593
PRAX icon
1149
Praxis Precision Medicines
PRAX
$8.1B
$5K ﹤0.01%
+62
New +$4.49K
XLI icon
1150
State Street Industrial Select Sector SPDR ETF
XLI
$32.5B
$5K ﹤0.01%
41
+31
+310% +$4.27K

Similar funds

Daiwa Securities Group's Q4 2024 Portfolio in Review

As of Q4 2024, Daiwa Securities Group held 1,352 positions worth $22.4B, up 3.4% from $21.6B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Daiwa Securities Group deployed $687M of net new capital in Q4 2024, opening 72 new positions and adding to 666 existing holdings. Its largest new stake was Curbline Properties: 2,033,334 shares worth $47.2M.

By sector, the portfolio is most concentrated in Real Estate at 38% of assets, down from 42% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was iShares Core S&P 500 ETF, an estimated $118M trimmed.

  • Daiwa Securities Group's largest Q4 2024 buy was Curbline Properties: 2,033,334 shares worth $47.2M.
  • Daiwa Securities Group added most to American Tower in Q4 2024, an estimated $191M increase.
  • Daiwa Securities Group's biggest Q4 2024 reduction was iShares Core S&P 500 ETF, cutting an estimated $118M.
  • Daiwa Securities Group fully exited State Street SPDR S&P 500 ETF Trust in Q4 2024, selling an estimated $10.3M.
  • Daiwa Securities Group's ten largest holdings make up 32% of its $22.4B portfolio in Q4 2024.
  • Daiwa Securities Group opened 72 new positions and closed 71 in Q4 2024.
  • Daiwa Securities Group's portfolio value rose 3.4% quarter-over-quarter to $22.4B.

Based on Daiwa Securities Group's 13F filing for Q4 2024, filed 7 Feb 2025.